Watanabe, N., Kobayashi, T., Iwaki, M., Nogami, A., Wada, N., Shimizu, A., . . . Yoneda, M. Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. Wiley.
Chicago Style (17th ed.) CitationWatanabe, Naohiro, et al. Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. Wiley.
MLA (9th ed.) CitationWatanabe, Naohiro, et al. Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. Wiley.
Warning: These citations may not always be 100% accurate.